[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20210038622A1 - Uses of pulsatilla chinensis extract in preparing drug for treating viral and/or bacterial diseases - Google Patents

Uses of pulsatilla chinensis extract in preparing drug for treating viral and/or bacterial diseases Download PDF

Info

Publication number
US20210038622A1
US20210038622A1 US16/966,855 US201916966855A US2021038622A1 US 20210038622 A1 US20210038622 A1 US 20210038622A1 US 201916966855 A US201916966855 A US 201916966855A US 2021038622 A1 US2021038622 A1 US 2021038622A1
Authority
US
United States
Prior art keywords
mastitis
injection
cows
pulsatilla saponin
clinical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/966,855
Inventor
Shilin Yang
Zhetong SU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Inlu Weite Pharmaceutical Technology Co Ltd
Original Assignee
Sichuan Inlu Weite Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Inlu Weite Pharmaceutical Technology Co Ltd filed Critical Sichuan Inlu Weite Pharmaceutical Technology Co Ltd
Assigned to SICHUAN INLU WEITE PHARMACEUTICAL TECHNOLOGY CO., LTD. reassignment SICHUAN INLU WEITE PHARMACEUTICAL TECHNOLOGY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SU, ZHETONG, YANG, SHILIN
Publication of US20210038622A1 publication Critical patent/US20210038622A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the use of Pulsatilla Chinensis extract in the preparation of a medicament for treating viral and/or bacterial diseases.
  • Pulsatilla Chinensis (Bge.) Regel is a Pulsatilla plant of Ranunculaceae family, and the main medicinal part thereof is its dry roots.
  • the earliest record about Pulsatilla is “Shen Nong's Materia Medica ”. It has a bitter taste, is cool-natured, and returns to the stomach, kidney, and large intestine meridians.
  • the main functions of Pulsatilla are detumescence, cooling blood, stopping diarrhea, reducing internal heat, etc. Pulsatilla is traditionally used for the treatment of bacterial dysentery, and it also has good therapeutic effects on chill and fever symptoms, swelling and pain of eye.
  • Pulsatilla has a variety of pharmacological activities, mainly to improve the body's ability to recognize and resist foreign body invasion, reduce the proliferation rate of tumor cells, reduce the number of pathogenic microorganisms and effectively inhibit the oxidation reaction of free radicals.
  • the most potential application is in the development of new anti-inflammatory and anti-tumor drugs.
  • Pulsatilla Feng Xiuzhi et al. studied the role of Pulsatilla in cell apoptosis and believed that Pulsatilla had a good induction effect on gastric cancer cells.
  • cancer cell proliferation and DNA replication are related to the active ingredients of Pulsatilla , which can inhibit the growth of HL260 cells, and inhibit the proliferation of breast cancer cells (MCF-7), lung cancer cells (PG), colon cancer cells (SW480), malignant glioma cells (U87MG) and other tumor cells by inducing apoptosis.
  • MCF-7 breast cancer cells
  • PG lung cancer cells
  • SW480 colon cancer cells
  • U87MG malignant glioma cells
  • Li Wenchao et al. applied Pulsatilla alcohol extract to various pathogenic bacteria and studied the antibacterial effect of different solvent extracts. It was found that these extracts all have antibacterial effects, although the effects are different.
  • Dariy cow mastitis is one of the three major cow diseases recognized in the world. It occurs frequently during lactation. The main reason for its occurrence is pathogenic microbial infection. Other causes include improper milking operations, mechanical damage caused by trauma and damage caused by chemical reagents. Dairy cow mastitis not only affects milk production and causes economic losses, but also affects the quality of milk and harms human health.
  • Dairy cow mastitis can be divided into two major categories: latent mastitis and clinical mastitis.
  • Clinical mastitis shows obvious clinical symptoms and visible changes in milk, and can be divided into three grades according to the degree of onset: Grade 1: abnormal milk; Grade 2: abnormal milk, the udder becomes hot, painful and enlarged; Grade 3: abnormal milk, the udder becomes hot, painful and enlarged, cows show symptoms of systemic infection.
  • Clinical mastitis is currently the main target of treatment in clinical practice. When cows with clinical mastitis are revealed, isolation treatment is required.
  • Latent mastitis also known as subclinical mastitis, is the most common type of mastitis in dairy cows.
  • This type of mastitis generally has no clinical symptom, the difference between its milk and normal milk cannot be distinguished by the naked eye, and it needs laboratory reagents to diagnose. In addition, if this type of mastitis does not reach a certain proportion in the herd, it is generally not treated. Because of its concealed incidence, the economic loss caused by latent mastitis to dairy cows is very serious.
  • the treatment of dairy cow mastitis mostly adopts methods such as udder infusion and intravenous injection, and the therapeutic drugs used are mostly antibiotic drugs, such as cefquinome, enrofloxacin, penicillin, streptomycin and the like.
  • antibiotic drugs such as cefquinome, enrofloxacin, penicillin, streptomycin and the like.
  • long-term use of antibiotics is prone to drug resistance and affects the treatment effect; at the same time, when antibiotics are used for treatment, it is easy to cause antibiotic residues, pollute milk sources, and endanger human health.
  • lactam antibiotics will destroy the cell wall and release endotoxin, causing redness, swelling, heat, and pain in the entire udder area, which will aggravate the condition. Therefore, it is of great significance to find a safe and effective method to treat dairy cow mastitis.
  • the present invention provides the use of the compound Pulsatilla Saponin B4 represented by formula I, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral and/or bacterial diseases:
  • the medicament is a preparation prepared from the aforementioned compound Pulsatilla Saponin B4 or a pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable auxiliary materials.
  • the preparation is an injection, an intramammary infusion, powder, ointment, lotion; preferably, the preparation is an injection, an intramammary infusion; more preferably, the preparation is an injection.
  • the disease is dairy cow mastitis.
  • the dairy cow mastitis is clinical mastitis, latent mastitis.
  • the clinical mastitis is clinical mastitis treated for the first time, persistent clinical mastitis, i.e., clinical mastitis that has been treated for a long time but not cured.
  • the present invention also provides a medicament for treating viral and/or bacterial diseases, which is a preparation prepared from the aforementioned compound Pulsatilla Saponin B4 or a pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable auxiliary materials.
  • the preparation is an injection, an intramammary infusion, powder, ointment, lotion; preferably, the preparation is an injection, an intramammary infusion; more preferably, the preparation is an injection.
  • the disease is dairy cow mastitis.
  • the dairy cow mastitis is clinical mastitis, latent mastitis; preferably, the clinical mastitis is clinical mastitis treated for the first time, persistent clinical mastitis.
  • the Pulsatilla extract provided by the present invention is the compound Pulsatilla Saponin B4, and its English name is Anemoside B4. Its CAS number is 129741-57-7, molecular formula is C 59 H 96 O 26 , molecular weight is 1221.38, and it is a white crystalline powder.
  • Pulsatilla Saponin B4 is a natural active ingredient extracted from Chinese herbal medicine Pulsatilla , is non-toxic and non-drug-resistant.
  • the compound Pulsatilla Saponin B4 of the present invention has strong biological activity and has excellent therapeutic effect on dairy cow mastitis. There is no need to discard the milk during the treatment and at the end of the treatment, which not only reduces the economic losses for farmers, but also reduces the risk of drug resistance.
  • Pulsatilla Saponin B4 not only has an excellent therapeutic effect on clinical mastitis, but also has an excellent therapeutic effect on persistent clinical mastitis and latent mastitis.
  • Pulsatilla saponin injection has the advantages of safety, high efficiency, no residue, no drug resistance, and no toxic and side effects when used in the treatment of dairy cow mastitis.
  • FIG. 1 is a standard curve for Pulsatilla Saponin B4 content determination.
  • FIG. 2 is a comparison of milk of cows suffering from clinical mastitis before and after treatment with Pulsatilla Saponin B4 injection.
  • FIG. 3 is a comparison of milk of cows suffering from clinical mastitis before and after treatment with Pulsatilla Saponin B4 injection.
  • FIG. 4 shows the treatment result of No. 8558, a cow that has been treated for a long time but not cured.
  • FIG. 5 shows the treatment result of cows with latent mastitis.
  • Agilent 1260 high-performance liquid chromatograph and DAD ultraviolet detector were purchased from Agilent Technologies (China) Co., Ltd., BP211D electronic analytical balance was purchased from Germany Sartorius company, and KQ-400 DB numerical control ultrasonic cleaner was purchased from Kunshan Ultrasonic Instrument Co., Ltd.
  • Pulsatilla Saponin B4 reference substance (lot number: 111766-201702, content: 94.7%) was purchased from National Institutes for Food and Drug Control.
  • Chromatography column Sepax Bio-C18 (4.6 ⁇ 250 mm, 5 ⁇ m); mobile phase: methanol-water (64:36); detection wavelength: 201 nm; flow rate: 1.0 mL/min.
  • Pulsatilla Saponin B4 Accurately weigh an appropriate amount of Pulsatilla Saponin B4 reference substance, place it into a 10 mL volumetric flask, add mobile phase to dissolve, and bring the volume to the mark to obtain the reference substance solution (containing 1 mg/ml of Pulsatilla Saponin B4).
  • Pulsatilla Saponin B4 reference substance Take Pulsatilla Saponin B4 reference substance, weigh accurately and place it into a 10 mL volumetric flask, add mobile phase to dissolve, bring the volume to the mark to prepare reference substance solutions with concentration of about 1 mg/mL, 5 mg/mL, 10 mg/mL, 15 mg/mL and 20 mg/mL respectively. Accurately measure 20 ⁇ L of each solution and inject it into the liquid chromatograph, and record the chromatogram.
  • Formulation 1000 mL injection solution made from 50 g Pulsatilla saponin B4 with water.
  • Formulation 1000 g powder made from 1000 g of Pulsatilla Saponin B4.
  • Current administration routes for treating mastitis include udder infusion, intramuscular injection, and intravenous injection.
  • udder infusion is the most common route of administration.
  • the therapeutic drugs are directly injected into the affected udder area through the nipple to achieve the effect of local administration and precision therapy.
  • Aonaikang , Cefquinome Sulfate Intramammary Infusion
  • Ruchang Cefotifur Injection
  • Intramuscular injection is to inject drugs into the muscle tissue of animals, so that the drugs reach the affected udder area through the blood circulation and exert the therapeutic effect. Intramuscular injection is easy to administer and can control the symptoms of systemic inflammation and fever caused by mastitis to a certain extent.
  • Intravenous injection is to inject the drug directly into the animal's venous blood, so that the drugs reach the affected udder area through the blood circulation.
  • the drug reaches the site of action quickly and can treat systemic symptoms.
  • intravenous injection has certain requirements for the properties of the drug, which cannot be a suspension and has little irritation to blood vessels.
  • Bayer Germany recommends the treatment of mastitis by intravenous injection of its product Baytrli (Enrofloxacin), which can reach a higher concentration in the affected udder area and exert the therapeutic effect there, and at the same time, can control systemic infections.
  • Intramuscular injection administration in the affected udder area Pulsatilla Saponin B4 injection is used for local intramuscular injection in the affected udder area, once every morning and evening for 7 days;
  • Intravenous injection administration Pulsatilla Saponin B4 injection is administered via intravenous injection once a day for 7 days;
  • Intramammary infusion administration Pulsatilla Saponin B4 intramammary infusion and the positive control (Cefquinome Sulfate Intramammary Infusion) are administered via intraductal infusion in the affected udder area, once every morning and evening for 7 days.
  • Each administration route of Pulsatilla saponin B4 of the present invention is provided with a blank control group, which is administered with normal saline at the same volume.
  • Clinically cured The clinical symptoms such as redness, swelling, heat, and pain in the affected udder area substantially disappeared, and lactation substantially recovered to normal.
  • the cure rate is calculated as following:
  • Cure ⁇ ⁇ rate number ⁇ ⁇ of ⁇ ⁇ completely ⁇ ⁇ cured ⁇ ⁇ cows + number ⁇ ⁇ of ⁇ ⁇ clinically ⁇ ⁇ cured ⁇ ⁇ cows number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ in ⁇ ⁇ experimental ⁇ ⁇ group ⁇ 100 ⁇ %
  • the total cure rate and cure time of Pulsatilla saponins B4 administrated via different administration routes are shown in Table 4: All the routes of administration have significant effects in the treatment of dairy cow mastitis, and the cure rates of the high-dose group of each route of administration are higher than that of the positive control (Cefquinome Sulfate Intramammary Infusion). Among them, intramuscular injection of Pulsatilla Saponin B4 injection has the best healing effect and the shortest treatment period.
  • Pulsatilla Saponin B4 injection prepared by the preparation method of Example 3 at a concentration of 50 mg/mL;
  • Control drug SHUANGDING Injection ( ) (10 mL/piece, batch number: DV3180701), Hebei Yuanzheng Pharmaceutical Co., Ltd.
  • Dosage Mode of Group (mL/kg BW) administration Blank control group Normal Intramuscular saline injection Positive drug control group 0.1 Intramuscular injection Pulsatilla Saponin B4 injection, intra- 0.025 Intramuscular muscular injection, low-dose group injection Pulsatilla Saponin B4 injection, intra- 0.05 Intramuscular muscular injection, medium-dose group injection Pulsatilla Saponin B4 injection, intra- 0.1 Intramuscular muscular injection, high-dose group injection
  • Days ⁇ ⁇ 2 ⁇ - ⁇ 7 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ cured ⁇ ⁇ on ⁇ ⁇ Days ⁇ ⁇ 2 ⁇ - ⁇ 7 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ in ⁇ ⁇ experimental ⁇ ⁇ group ⁇ 100 ⁇ % ;
  • the cure rate within 7 days is the sum of the daily cure rate of treatment on Days 2-7.
  • Days ⁇ ⁇ 2 ⁇ - ⁇ 7 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ effectively ⁇ ⁇ treated ⁇ ⁇ on ⁇ ⁇ Days ⁇ ⁇ 2 ⁇ - ⁇ 7 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ in ⁇ ⁇ experimental ⁇ ⁇ group ⁇ 100 ⁇ % ;
  • the effective rate within 7 days is the sum of the daily effective rate of treatment on Days 2-7.
  • Recurrence rate During the period from D5 to D12, if the diseased cow judged as successfully treated meets “the sum of scores>2” after withdrawal of the drug, it is regarded as recurrence.
  • Recurrence ⁇ ⁇ rate number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ recurred ⁇ ⁇ after ⁇ ⁇ successfully ⁇ ⁇ treated number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ successfully ⁇ ⁇ treated ⁇ 100 ⁇ % .
  • Cure rate of treatment on Day 12 (total cure rate): On D12, if the cow suffering from mastitis meets “the sum of scores ⁇ 1”, it is regarded as cured on Day 12. The cure rate on
  • Day ⁇ ⁇ 12 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ cured ⁇ ⁇ on ⁇ ⁇ Day ⁇ ⁇ 12 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ in ⁇ ⁇ experimental ⁇ ⁇ group ⁇ 100 ⁇ % .
  • Effective rate of treatment on Day 12 (total effective rate): On D12, if the cow suffering from mastitis meets “1 ⁇ the sum of the scores ⁇ 2”, the treatment is considered effective. The effective rate on Day 12
  • Day ⁇ ⁇ 12 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ effectively ⁇ ⁇ treated ⁇ ⁇ on ⁇ ⁇ Day ⁇ ⁇ 12 number ⁇ ⁇ of ⁇ ⁇ cows ⁇ ⁇ in ⁇ ⁇ experimental ⁇ ⁇ group ⁇ 100 ⁇ % .
  • the clinical symptom examination score of dairy cows with mastitis in medium-dose group was not significantly different between D0-D1, between D2-D5, and between D4-D12 (p>0.05), but was significantly different between D3-D12 and D0-D2, between D6-D12 and D0-D3 (p ⁇ 0.05), indicating that in medium-dose group, cows improved significantly at D3, and cured significantly at D6.
  • the clinical symptom examination score of dairy cows with mastitis in high-dose group was not significantly different between D0-D3, between D1-D5, between D3-D6, and between D7-D12 (p>0.05), but was significantly different between D4-D12 and D0, between D6-D12 and D0-D2, and between D7-D12 and D0-D6 (p ⁇ 0.05), indicating that in high-dose group, cows with mastitis generally started to improve at D4, the number of cured cows has increased significantly at D6, and some cows cured at D7.
  • the clinical symptom examination score of dairy cows with mastitis in control group was not significantly different between D0-D4, between D2-D6, and between D3-D12 (p>0.05), but was significantly different between D5-D12 and D0-D4, and between D7-D12 and D0-D6 (p ⁇ 0.05), indicating that in control group, cows improved at D5, and a certain number of cows cured at D7.
  • the clinical symptom examination score of medium-dose group at D0 was significantly higher than those of the low-dose group and high-dose group (p ⁇ 0.05), indicating that the disease of cows in the medium-dose group was more serious; the clinical symptom examination score of medium-dose group at D1 was significantly higher than the other 3 groups (p ⁇ 0.05), the clinical symptom examination score of medium-dose group at D2 was significantly higher than those of the low-dose group and high-dose group (p ⁇ 0.05), indicating that in the early stage of treatment, the medium-dose group has an obvious effect on improving the clinical symptoms of cows with mastitis; the differences in the clinical symptom examination score of cows between the four groups at D3-D5 and D7 were not significant (p>0.05); the clinical symptom examination score of the cows in the control group at D12 was significantly higher than that of the high-dose group (p ⁇ 0.05), indicating that the therapeutic effect of the control group is inferior to that of the Pulsatilla treatment group.
  • G means “Group”
  • N means “Number of cattle”
  • L means “Low-dose group”
  • M means “Medium-dose group”
  • H means “High-dose group”
  • C means “Control group”
  • milk somatic cells of the four groups of cows at D0 were not significant, indicating that from the perspective of milk somatic cells, the cows in each group had similar disease status at the time of onset.
  • the milk somatic cells of the medium-dose group cows were significantly lower than those of the high-dose group and the control group, which was related to the shorter average cure time of the medium-dose group.
  • the milk somatic cells of the cows in the control group were significantly higher than that of the medium-dose group, indicating that the therapeutic effect of Pulsatilla Saponin B4 injection on dairy cow mastitis is better than SHUANGDING Injection.
  • Pulsatilla Saponin B4 injection is non-toxic and non-drug-resistant, and there is no need to discard the milk during the treatment and at the end of the treatment, which not only reduces the economic losses for farmers, but also reduces the risk of drug resistance.
  • FIGS. 2 and 3 show the comparison of milk of cows with clinical mastitis before and after treatment with Pulsatilla Saponin B4 injection.
  • the cows with clinical mastitis had more flocs in the milk.
  • the flocs gradually decreased, and the milk gradually returned to normal.
  • the milk returned to normal. It showed that Pulsatilla Saponin B4 injection has a significant effect in treating clinical mastitis and improving milk quality.
  • Pulsatilla Saponin B4 injection prepared by the preparation method of Example 3 at a concentration of 50 mg/mL;
  • the test selected 8 existing cows suffering from clinical mastitis in the dairy farm of Shijiazhuang Tianquan Dairy Cows Co., Ltd. These 8 cows have been treated for about a month but have not been cured (2 of them were close to dry, i.e., almost no milk was produced). These 8 cows have been treated by farm veterinarians, the treatment drugs and methods include udder infusing Cefquinome Sulfate Intramammary Infusion, intravenous injecting cephalosporins injection, and gavage with Gongying San ( ), etc.
  • the Pulsatilla Saponin B4 injection prepared by the preparation method of Example 3 was used to treat 6 cows with persistent clinical mastitis and 2 cows with persistent clinical mastitis and close to dry. No matter how many udder areas were inflamed, intramuscular injection (60 mL) was taken once a day.
  • Treatment results for some cows that have not been cured for a long time For the cow with an ear-tag numbered 8558, the milk of the cow before treatment was thin and contained a small amount of flocs, and the LMT test result was “+++”; after intramuscular injection of 60 mL Pulsatilla Saponin B4 injection once, there was no visible flocs in the milk, and the color of the milk was slightly yellow. After the second administration, milk returned to normal, and the result of LMT test by the veterinarian was “++”. Then the cow was transferred to the farm housing by the veterinarian.
  • FIG. 4 shows the treatment of the cow numbered 8558, which has not been cured for a long time. It can be seen from FIG. 4 that as the treatment time increases, the milk secretion of the cow numbered 8558 gradually became normal. After 2 times of administration, the milk returned to normal, the cow was clinically cured.
  • FIG. 5 shows the treatment results of some cows suffering from latent mastitis after three days of treatment with Pulsatilla Saponin B4 injection. It can be seen from FIG. 5 that the condition of cows suffering from latent mastitis improved after administration of medication.
  • Pulsatilla Saponin B4 has a good effect on latent mastitis.
  • the diseased cows have been treated by farm veterinarians via udder infusing Cefquinome Sulfate Intramammary Infusion, intravenous injecting cephalosporins injection, and gavage with Gongying San ( ) for about a month, but the treatment was ineffective, and the disease was then turned into chronic mastitis, which was manifested by thin milk and continuous floc in the milk.
  • the reason for the above situation may be: first, the variety of drug used in the farm for the treatment of mastitis was simplex, only antibacterial drug was used in the treatment process without paying attention to anti-inflammatory; second, the variety of antibiotics used was simplex, and the pathogenic bacteria were not isolated and identified, resulting in bacterial resistance and insensitivity to drugs; third, long-term treatment leads to hyperplasia of mammary tissue, causing chronic inflammation, which in turn makes it more difficult for the drug to reach the effective site, making the condition stubborn.
  • Pulsatilla Saponin B4 injection was used to treat 8 cows recruited in the test, after 3 administrations, four cows were cured, one cow improved significantly, and one cow showed no significant effect; it was not effective for two cows close to dry. The results of the study showed that Pulsatilla Saponin B4 has a good effect on dairy cow mastitis for which treatment with antibiotics or other means are ineffective.
  • Latent mastitis is one of the most common types of mastitis in dairy cows. This type of mastitis generally has no clinical symptom, the difference between its milk and normal milk cannot be distinguished by the naked eye, and it needs laboratory reagents to diagnose. If this type of mastitis does not reach a certain proportion in the herd, it is generally not treated. Because of its concealed incidence, the economic loss caused by latent mastitis to dairy cows is very serious. When Pulsatilla Saponin B4 injection was used to treat 6 cows suffering from latent mastitis, four cows improved; one cow showed significant effect and reduced somatic cells in the LMT test; one cow had no significant improvement. The results of the study showed that Pulsatilla Saponin B4 has a good effect on latent mastitis.
  • Pulsatilla Saponin B4 has little effect on the immunoglobulin and inflammatory factors in the cow milk, thus can ensure the stability of the milk composition. In addition, since there is no residue, it will not affect the quality of fresh milk in dairy farms.
  • Pulsatilla Saponin B4 is a natural active ingredient extracted from Chinese herbal medicine Pulsatilla , is non-toxic and non-drug-resistant.
  • the compound Pulsatilla Saponin B4 of the present invention has strong biological activity and has excellent therapeutic effect on dairy cow mastitis. There is no need to discard the milk during the treatment and at the end of the treatment, which not only reduces the economic losses for farmers, but also reduces the risk of drug resistance.
  • Pulsatilla Saponin B4 not only has an excellent therapeutic effect on clinical mastitis, but also has an excellent therapeutic effect on persistent clinical mastitis and latent mastitis.
  • Pulsatilla saponin injection has the advantages of safety, high efficiency, no residue, no drug resistance, and no toxic and side effects when used in the treatment of dairy cow mastitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of the compound Pulsatilla Saponin B4 represented by formula (I), or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral and/or bacterial diseases, and a medicament comprising the compound Pulsatilla Saponin B4 represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease is dairy cow mastitis.
Figure US20210038622A1-20210211-C00001

Description

    TECHNICAL FIELD
  • The present invention relates to the use of Pulsatilla Chinensis extract in the preparation of a medicament for treating viral and/or bacterial diseases.
    • BACKGROUND
  • Pulsatilla Chinensis (Bge.) Regel is a Pulsatilla plant of Ranunculaceae family, and the main medicinal part thereof is its dry roots. The earliest record about Pulsatilla is “Shen Nong's Materia Medica”. It has a bitter taste, is cool-natured, and returns to the stomach, kidney, and large intestine meridians. The main functions of Pulsatilla are detumescence, cooling blood, stopping diarrhea, reducing internal heat, etc. Pulsatilla is traditionally used for the treatment of bacterial dysentery, and it also has good therapeutic effects on chill and fever symptoms, swelling and pain of eye. Pulsatilla has a variety of pharmacological activities, mainly to improve the body's ability to recognize and resist foreign body invasion, reduce the proliferation rate of tumor cells, reduce the number of pathogenic microorganisms and effectively inhibit the oxidation reaction of free radicals. Among them, the most potential application is in the development of new anti-inflammatory and anti-tumor drugs.
  • Feng Xiuzhi et al. studied the role of Pulsatilla in cell apoptosis and believed that Pulsatilla had a good induction effect on gastric cancer cells. In addition, cancer cell proliferation and DNA replication are related to the active ingredients of Pulsatilla, which can inhibit the growth of HL260 cells, and inhibit the proliferation of breast cancer cells (MCF-7), lung cancer cells (PG), colon cancer cells (SW480), malignant glioma cells (U87MG) and other tumor cells by inducing apoptosis. Li Wenchao et al. applied Pulsatilla alcohol extract to various pathogenic bacteria and studied the antibacterial effect of different solvent extracts. It was found that these extracts all have antibacterial effects, although the effects are different.
  • Dariy cow mastitis is one of the three major cow diseases recognized in the world. It occurs frequently during lactation. The main reason for its occurrence is pathogenic microbial infection. Other causes include improper milking operations, mechanical damage caused by trauma and damage caused by chemical reagents. Dairy cow mastitis not only affects milk production and causes economic losses, but also affects the quality of milk and harms human health.
  • Dairy cow mastitis can be divided into two major categories: latent mastitis and clinical mastitis. Clinical mastitis shows obvious clinical symptoms and visible changes in milk, and can be divided into three grades according to the degree of onset: Grade 1: abnormal milk; Grade 2: abnormal milk, the udder becomes hot, painful and enlarged; Grade 3: abnormal milk, the udder becomes hot, painful and enlarged, cows show symptoms of systemic infection. Clinical mastitis is currently the main target of treatment in clinical practice. When cows with clinical mastitis are revealed, isolation treatment is required. Latent mastitis, also known as subclinical mastitis, is the most common type of mastitis in dairy cows. This type of mastitis generally has no clinical symptom, the difference between its milk and normal milk cannot be distinguished by the naked eye, and it needs laboratory reagents to diagnose. In addition, if this type of mastitis does not reach a certain proportion in the herd, it is generally not treated. Because of its concealed incidence, the economic loss caused by latent mastitis to dairy cows is very serious.
  • At present, the treatment of dairy cow mastitis mostly adopts methods such as udder infusion and intravenous injection, and the therapeutic drugs used are mostly antibiotic drugs, such as cefquinome, enrofloxacin, penicillin, streptomycin and the like. However, long-term use of antibiotics is prone to drug resistance and affects the treatment effect; at the same time, when antibiotics are used for treatment, it is easy to cause antibiotic residues, pollute milk sources, and endanger human health. It is worth noting that if mastitis is a Gram-negative bacterial infection, the use of lactam antibiotics will destroy the cell wall and release endotoxin, causing redness, swelling, heat, and pain in the entire udder area, which will aggravate the condition. Therefore, it is of great significance to find a safe and effective method to treat dairy cow mastitis.
  • At present, there are no reports on the use of the compounds of the present invention for the treatment of viral and/or bacterial mastitis in dairy cows.
    • SUMMARY OF THE INVENTION
  • In order to solve the above technical problem, the present invention provides the use of the compound Pulsatilla Saponin B4 represented by formula I, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral and/or bacterial diseases:
  • Figure US20210038622A1-20210211-C00002
  • In a further aspect, the medicament is a preparation prepared from the aforementioned compound Pulsatilla Saponin B4 or a pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable auxiliary materials.
  • In a further aspect, the preparation is an injection, an intramammary infusion, powder, ointment, lotion; preferably, the preparation is an injection, an intramammary infusion; more preferably, the preparation is an injection.
  • In a further aspect, the disease is dairy cow mastitis.
  • In a further aspect, the dairy cow mastitis is clinical mastitis, latent mastitis.
  • In a further aspect, the clinical mastitis is clinical mastitis treated for the first time, persistent clinical mastitis, i.e., clinical mastitis that has been treated for a long time but not cured.
  • The present invention also provides a medicament for treating viral and/or bacterial diseases, which is a preparation prepared from the aforementioned compound Pulsatilla Saponin B4 or a pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable auxiliary materials.
  • In a further aspect, the preparation is an injection, an intramammary infusion, powder, ointment, lotion; preferably, the preparation is an injection, an intramammary infusion; more preferably, the preparation is an injection.
  • In a further aspect, the disease is dairy cow mastitis.
  • In a further aspect, the dairy cow mastitis is clinical mastitis, latent mastitis; preferably, the clinical mastitis is clinical mastitis treated for the first time, persistent clinical mastitis.
  • The Pulsatilla extract provided by the present invention is the compound Pulsatilla Saponin B4, and its English name is Anemoside B4. Its CAS number is 129741-57-7, molecular formula is C59H96O26, molecular weight is 1221.38, and it is a white crystalline powder.
  • At present, antibiotics are mostly used for the treatment of mastitis. Among them, broad-spectrum sterilization and cell-damaging nucleic acid antibiotics are more commonly used. During the treatment and 4 to 5 days after the treatment, milk needs to be discarded, causing a large economic loss to the farmers and the risk of drug resistance. Pulsatilla Saponin B4 is a natural active ingredient extracted from Chinese herbal medicine Pulsatilla, is non-toxic and non-drug-resistant. The compound Pulsatilla Saponin B4 of the present invention has strong biological activity and has excellent therapeutic effect on dairy cow mastitis. There is no need to discard the milk during the treatment and at the end of the treatment, which not only reduces the economic losses for farmers, but also reduces the risk of drug resistance. In addition, Pulsatilla Saponin B4 not only has an excellent therapeutic effect on clinical mastitis, but also has an excellent therapeutic effect on persistent clinical mastitis and latent mastitis. At the same time, Pulsatilla saponin injection has the advantages of safety, high efficiency, no residue, no drug resistance, and no toxic and side effects when used in the treatment of dairy cow mastitis.
  • Obviously, according to the above-mentioned contents of the present invention, in accordance with the ordinary technical knowledge and conventional technical means in the art, various forms of modification, replacement or alteration can be made without departing from the above basic technical idea of the present invention.
  • The above contents of the present invention will be further described in detail below by way of specific embodiments in the form of examples. However, it should not be construed that the scope of the above subject matter of the present invention is limited to the following examples. All technologies implemented based on the above contents of the present invention belong to the scope of the present invention.
    • DRAWINGS
  • FIG. 1 is a standard curve for Pulsatilla Saponin B4 content determination.
  • FIG. 2 is a comparison of milk of cows suffering from clinical mastitis before and after treatment with Pulsatilla Saponin B4 injection.
  • FIG. 3 is a comparison of milk of cows suffering from clinical mastitis before and after treatment with Pulsatilla Saponin B4 injection.
  • FIG. 4 shows the treatment result of No. 8558, a cow that has been treated for a long time but not cured.
  • FIG. 5 shows the treatment result of cows with latent mastitis.
    •  EMBODIMENTS Example 1. Preparation of the Compound of the Present Invention
  • Take 100 kg of Pulsatilla medicinal material, add 10 times the amount of 70% ethanol and extract twice by heating and refluxing. The extract is concentrated under reduced pressure at 75° C., centrifuged at 4000 r/min for 10 minutes. The supernatant is passed through a polar macroporous adsorption resin column, and then eluted sequentially with water, 30% ethanol, and 70% ethanol. The fraction eluted with 70% ethanol is concentrated under reduced pressure at 75° C., and then spray-dried to obtain 3450 g of total Pulsatilla saponin extract. After dissolving the extract with water and filtering, the filtrate is loaded on a dynamic axial 200 preparative chromatographic system (filled with 10 μm ODS), eluted with 50% methanol, the corresponding eluent is collected according to the chromatographic peak, concentrated under reduced pressure, and freeze-dried to obtain 1700 g of Pulsatilla Saponin B4.
    • Example 2. Content Determination of the Compound of the Present Invention 1. Instruments and Reagents
  • Agilent 1260 high-performance liquid chromatograph and DAD ultraviolet detector were purchased from Agilent Technologies (China) Co., Ltd., BP211D electronic analytical balance was purchased from Germany Sartorius company, and KQ-400 DB numerical control ultrasonic cleaner was purchased from Kunshan Ultrasonic Instrument Co., Ltd.
  • Sample of Pulsatilla Saponin B4, prepared in Example 1.
  • Pulsatilla Saponin B4 reference substance (lot number: 111766-201702, content: 94.7%) was purchased from National Institutes for Food and Drug Control.
    • 2. Chromatographic Conditions
  • Chromatography column: Sepax Bio-C18 (4.6×250 mm, 5 μm); mobile phase: methanol-water (64:36); detection wavelength: 201 nm; flow rate: 1.0 mL/min.
    • 3. Preparation of Reference Substance Solution
  • Accurately weigh an appropriate amount of Pulsatilla Saponin B4 reference substance, place it into a 10 mL volumetric flask, add mobile phase to dissolve, and bring the volume to the mark to obtain the reference substance solution (containing 1 mg/ml of Pulsatilla Saponin B4).
    • 4. Preparation of Sample Solution
  • Accurately weigh 10 mg sample of Pulsatilla Saponin B4 prepared in Example 1, place it into a 10 mL volumetric flask, add mobile phase to dissolve, and bring the volume to the mark to obtain the sample solution.
    • 5. Determination
  • Accurately measure 20 μL each of the reference solution and the sample solution, inject it into the liquid chromatograph, record the chromatogram, and calculate the content according to the external standard method.
    • 6. Standard Curve and Linear Regression Equation
  • Take Pulsatilla Saponin B4 reference substance, weigh accurately and place it into a 10 mL volumetric flask, add mobile phase to dissolve, bring the volume to the mark to prepare reference substance solutions with concentration of about 1 mg/mL, 5 mg/mL, 10 mg/mL, 15 mg/mL and 20 mg/mL respectively. Accurately measure 20 μL of each solution and inject it into the liquid chromatograph, and record the chromatogram.
  • TABLE 1
    Linear regression equation for content determination of
    Pulsatilla Saponin B4 reference substance
    Concentration Peak Regression
    Sample (mg/mL) area equation
    1 0.98488 115.7 Y = 100.07 + 10.721
    2 4.92440 529.5 R = 0.9999
    3 9.84880 1057.8
    4 14.77320 1560.3
    5 19.69760 2097.9
  • It can be seen from the experimental results that Pulsatilla Saponin B4 has a good linear relationship in the concentration range of 1.04-20.80 mg/mL, R=0.9999, and is suitable for the content determination of Pulsatilla Saponin B4.
    • 7. Content Determination of Pulsatilla Saponin B4 Sample
  • According to the method described in “3” above, accurately weigh 2 parts of Pulsatilla Saponin B4 reference substance, 10 mg each, place it into a 10 mL volumetric flask, add mobile phase to dissolve, and bring the volume to the mark to obtain Reference solution 1 and Reference solution 2.
  • According to the method described in “4” above, accurately weigh 2 parts of Pulsatilla Saponin B4 sample, 10 mg each, place it into a 10 mL volumetric flask, add mobile phase to dissolve, and bring the volume to the mark to obtain Sample solution 1 and Sample solution 2.
  • According to the above chromatographic conditions, accurately measure 20 μL of each solution, inject it into the liquid chromatograph, and record the chromatogram.
  • TABLE 2
    Results of content determination of Pulsatilla Saponin B4
    Weight Peak Conc. Content Average
    Sample (mg) Area (mg/mL) (%) content (%)
    Reference 10.22 1039.6 0.968 // //
    solution 1 1044.4
    Reference 10.05 1025.6 0.952 // //
    solution 2 1022.5
    Sample 10.13 1081.8 1.013 99.7 99.4
    solution 1 1092.6
    Sample 10.10 1075.1 1.010 99.1
    solution 2 1079.2
  • According to the test results, the content of Pulsatilla Saponin B4 obtained in this experiment was 99.4%.
    • Example 3. Preparation of Pulsatilla Saponin B4 Injection
  • 1) Formulation: 1000 mL injection solution made from 50 g Pulsatilla saponin B4 with water.
  • 2) Preparation method: Weigh 50 g of Pulsatilla Saponin B4 prepared in Example 1, add 800 mL of water for injection to dissolve it completely, filter, adjust pH to 7.0, add water for injection to a volume of 1000 mL, fine filter, fill into a container, seal and sterilize at 100° C. for 30 min.
    • Example 4. Preparation of Pulsatilla Saponin B4 Powder
  • 1) Formulation: 1000 g powder made from 1000 g of Pulsatilla Saponin B4.
  • 2) Preparation method: Weigh 1000 g of Pulsatilla Saponin B4 prepared in Example 1, pulverize it into a fine powder, pass through a 100-mesh sieve, and mix well.
    • Example 5. Preparation of Pulsatilla Saponin B4 Intramammary Infusion
  • 1) Formulation: 1000 mL intramammary infusion made from 50 g Pulsatilla Saponin B4.
  • 2) Preparation method: Weigh 50 g of Pulsatilla Saponin B4 prepared in Example 1, add 800 mL of distilled water to dissolve it completely, filter, adjust pH to 7.0, add distilled water to a volume of 1000 mL, fine filter, fill into a container, seal, sterilize at 100° C. for 30 min.
  • The beneficial effects of the present invention will be described below by way of test examples.
    • Test Example 1. Effects of Different Administration Routes of the Compound of the Present Invention on the Therapeutic Effect of Dairy Cow Mastitis
  • Current administration routes for treating mastitis include udder infusion, intramuscular injection, and intravenous injection.
  • Among them, udder infusion is the most common route of administration. The therapeutic drugs are directly injected into the affected udder area through the nipple to achieve the effect of local administration and precision therapy. At present, there are a variety of commercial pharmaceutical preparations for udder infusion, such as Aonaikang (
    Figure US20210038622A1-20210211-P00001
    , Cefquinome Sulfate Intramammary Infusion) by Eastern Along Pharmaceutical Co., Ltd., Ruchang (Cefotifur Injection) by Pfizer, etc.
  • Intramuscular injection is to inject drugs into the muscle tissue of animals, so that the drugs reach the affected udder area through the blood circulation and exert the therapeutic effect. Intramuscular injection is easy to administer and can control the symptoms of systemic inflammation and fever caused by mastitis to a certain extent.
  • Intravenous injection is to inject the drug directly into the animal's venous blood, so that the drugs reach the affected udder area through the blood circulation. By intravenous injection, the drug reaches the site of action quickly and can treat systemic symptoms. However, intravenous injection has certain requirements for the properties of the drug, which cannot be a suspension and has little irritation to blood vessels. Bayer (Germany) recommends the treatment of mastitis by intravenous injection of its product Baytrli (Enrofloxacin), which can reach a higher concentration in the affected udder area and exert the therapeutic effect there, and at the same time, can control systemic infections.
  • The above three routes of administration for treating dairy cow mastitis have their own advantages and disadvantages. This test aims to explore the therapeutic effect of Pulsatilla Saponin B4 on dairy cow mastitis and the most suitable route of administration. The results of this study will provide an important reference for how to make Pulsatilla Saponin B4 exert the best therapeutic effect, and for future development and packaging of the drug.
    • 1. Test Drugs
  • Pulsatilla Saponin B4 injection prepared in Example 3 at a concentration of 50 mg/mL; Pulsatilla Saponin B4 intramammary infusion prepared in Example 5 at a concentration of 50 mg/mL.
  • Positive control: Cefquinome Sulfate Intramammary Infusion, 8 g/piece (Eastern Along Pharmaceutical Co., Ltd., Nanhai, Foshan).
    • 2. Test Animals
  • 130 sick cows (grade 2 clinical mastitis) were selected and randomly divided into 13 groups with 10 cows in each group.
    • 3. Dosage and Mode of Administration
  • TABLE 3
    Dosage and mode of administration
    Dosage
    (mL/
    affected
    udder Mode of
    Group area/time) administration
    Blank control group Normal /
    saline
    Positive control group 1 Piece Intraductal
    infusion
    Pulsatilla Saponin B4 injection, 10 Intramuscular
    intramuscular injection, low-dose group injection
    Pulsatilla Saponin B4 injection, intra- 20 Intramuscular
    muscular injection, medium-dose group injection
    Pulsatilla Saponin B4 injection, 30 Intramuscular
    intramuscular injection, high-dose group injection
    Pulsatilla Saponin B4 injection, intra- 40 Intravenous
    venous injection, low-dose group injection
    Pulsatilla Saponin B4 injection, intra- 60 Intravenous
    venous injection, medium-dose group injection
    Pulsatilla Saponin B4 injection, intra- 80 Intravenous
    venous injection, high-dose group injection
    Pulsatilla Saponin B4 intramammary 20 Intraductal
    infusion, low-dose group infusion
    Pulsatilla Saponin B4 intramammary 30 Intraductal
    infusion, medium-dose group infusion
    Pulsatilla Saponin B4 intramammary 40 Intraductal
    infusion, high-dose group infusion
  • Intramuscular injection administration in the affected udder area: Pulsatilla Saponin B4 injection is used for local intramuscular injection in the affected udder area, once every morning and evening for 7 days;
  • Intravenous injection administration: Pulsatilla Saponin B4 injection is administered via intravenous injection once a day for 7 days;
  • Intramammary infusion administration: Pulsatilla Saponin B4 intramammary infusion and the positive control (Cefquinome Sulfate Intramammary Infusion) are administered via intraductal infusion in the affected udder area, once every morning and evening for 7 days.
  • Each administration route of Pulsatilla saponin B4 of the present invention is provided with a blank control group, which is administered with normal saline at the same volume.
    • 4. Evaluation Guide
  • Before each administration, check the cow's body temperature, breathing, mental status, feeding status and other indicators to observe the changes in the udder and milk.
  • Completely cured: The clinical symptoms such as redness, swelling, heat and pain in the affected udder area disappeared completely, and lactation recovered to normal.
  • Clinically cured: The clinical symptoms such as redness, swelling, heat, and pain in the affected udder area substantially disappeared, and lactation substantially recovered to normal.
  • Invalid: No significant improvement or even worsening of clinical symptoms in the affected udder area, or recurrence within two weeks of drug withdrawal, both are considered invalid.
  • The cure rate is calculated as following:
  • Cure rate = number of completely cured cows + number of clinically cured cows number of cows in experimental group × 100 %
    • 5. Results
  • TABLE 4
    Cure rate and cure time of dairy cows
    mastitis treated via different administration routes
    Cure Cure
    Group rate (%) time
    Blank control group  0 /
    Positive control group 60 5-7
    Pulsatilla Saponin B4 injection, 50 5-7
    intramuscular injection, low-dose group
    Pulsatilla Saponin B4 injection, 60 5-6
    intramuscular injection, medium-dose group
    Pulsatilla Saponin B4 injection, 80 4-6
    intramuscular injection, high-dose group
    Pulsatilla Saponin B4 injection, intravenous 40 5-7
    injection, low-dose group
    Pulsatilla Saponin B4 injection, intravenous 60 5-6
    injection, medium-dose group
    Pulsatilla Saponin B4 injection, intravenous 70 4-7
    injection, high-dose group
    Pulsatilla Saponin B4 intramammary 40 6-7
    infusion, low-dose group
    Pulsatilla Saponin B4 intramammary 50 5-6
    infusion, medium-dose group
    Pulsatilla Saponin B4 intramammary 70 4-7
    infusion, high-dose group
  • The total cure rate and cure time of Pulsatilla saponins B4 administrated via different administration routes are shown in Table 4: All the routes of administration have significant effects in the treatment of dairy cow mastitis, and the cure rates of the high-dose group of each route of administration are higher than that of the positive control (Cefquinome Sulfate Intramammary Infusion). Among them, intramuscular injection of Pulsatilla Saponin B4 injection has the best healing effect and the shortest treatment period.
    • Test Example 2. Study of Pulsatilla Saponin B4 of the Present Invention in the Treatment of Clinical Mastitis 1. Test Drugs
  • Pulsatilla Saponin B4 injection prepared by the preparation method of Example 3 at a concentration of 50 mg/mL;
  • Control drug: SHUANGDING Injection (
    Figure US20210038622A1-20210211-P00002
    ) (10 mL/piece, batch number: DV3180701), Hebei Yuanzheng Pharmaceutical Co., Ltd.
    • 2. Test Animals
  • 60 Chinese Holstein cows weighing approximately 612±47 kg, aged 3-5 years old, 2-4 parity, healthy in clinical examination and naturally occurring clinical mastitis during lactation period were selected and randomly divided into 5 groups, 12 in each group.
    • 3. Test Method 3.1 Dosage and Mode of Administration
  • TABLE 5
    Dosage and mode of administration
    Dosage Mode of
    Group (mL/kg BW) administration
    Blank control group Normal Intramuscular
    saline injection
    Positive drug control group 0.1 Intramuscular
    injection
    Pulsatilla Saponin B4 injection, intra- 0.025 Intramuscular
    muscular injection, low-dose group injection
    Pulsatilla Saponin B4 injection, intra- 0.05 Intramuscular
    muscular injection, medium-dose group injection
    Pulsatilla Saponin B4 injection, intra- 0.1 Intramuscular
    muscular injection, high-dose group injection
  • After the onset of test cows, record the day before administration as D0. Calculate the dosing amount based on body weight according to the pre-designed dosing substance and dosage (Table 5). Starting from the day D1, each group of cows with clinical mastitis was administered the test drug (Pulsatilla Saponin B4 injection) or the control drug (SHUANGDING Injection) by intramuscular injection, once a day for 4 to 7 days, depending on the cure of the disease. Observe the clinical symptoms of cows in each group before and after administration of the drug (D0˜D12), score according to the standard (see Table 6 for details), and make a record of dosing. At the end of the test (D12), based on the observation results of the above indicators, the therapeutic effect on each cow was judged according to the standard, and the cure rate and effective rate of each group of cows were calculated.
  • 3.2 Scoring Standard for Clinical Symptoms of Dairy Cows with Clinical Mastitis
  • At D0 (after the reveal of clinical mastitis, before administration), D1 (after the first administration, before the second administration), D2˜D7 (cured cows withdraw drug, and uncured cows continue to receive drug), D8˜D12 (all cows withdraw drug), regularly check the clinical symptoms and udder symptoms of each cow, such as mental state, appetite and drinking, etc., and score according to the following table (see Table 6). Record clinical symptoms (local udder symptom score).
  • TABLE 6
    Scoring standard for clinical
    symptoms of dairy cows with clinical mastitis
    Observations Score Scoring standard
    Mental state 0 Good
    1 Slightly worse
    2 Excited or depressed
    3 Lying on the floor or even comatose
    Appetite and 0 Strong appetite; moderate drinking
    drinking 1 Slightly reduced feeding; slightly decreased or
    increased drinking
    2 Significantly reduced feeding; severely
    decreased or increased drinking
    3 Loss of appetite; drink plenty of water
    or abstain from drinking
    Lactation 0 Normal milk production
    capacity 1 Reduced milk production
    2 Significantly reduced milk production
    3 Almost stop lactation
    Milk traits 0 Normal milk traits
    1 The milk has a small amount of flakes and clots
    2 There is a lot of clot in the milk
    3 Milk has traces of blood, pus, and obvious odor
    Local 0 Normal
    symptoms 1 Mild redness and swelling, no obvious
    of udder heat pain reaction on palpation
    2 Moderate redness and swelling, with heat
    pain reaction on palpation
    3 Severe redness and swelling, obvious heat
    pain reaction on palpation
    • 3.3 Detection Method of Somatic Cell Number in Cow Milk
  • Collect the milk of the cows suffering from clinical mastitis on D0, D7 and D12 of the test, detect and record the number of somatic cells.
    • 3.4 Evaluation of Efficacy Judging by the Clinical Symptom Examination Score
  • Daily cure rate of treatment on Days 2-7: Starting on D2, if the cow suffering from mastitis meets “the sum of scores<1”, the treatment is considered cured. Daily cure rate of treatment on
  • Days 2 - 7 = number of cows cured on Days 2 - 7 number of cows in experimental group × 100 % ;
  • the cure rate within 7 days is the sum of the daily cure rate of treatment on Days 2-7.
  • Daily effective rate of treatment on Days 2-7: Starting on D2, if the cow suffering from mastitis meets “1≤the sum of scores≤2”, the treatment is considered effective. Daily effective rate of treatment on
  • Days 2 - 7 = number of cows effectively treated on Days 2 - 7 number of cows in experimental group × 100 % ;
  • the effective rate within 7 days is the sum of the daily effective rate of treatment on Days 2-7.
  • Recurrence rate: During the period from D5 to D12, if the diseased cow judged as successfully treated meets “the sum of scores>2” after withdrawal of the drug, it is regarded as recurrence.
  • Recurrence rate = number of cows recurred after successfully treated number of cows successfully treated × 100 % .
  • Cure rate of treatment on Day 12 (total cure rate): On D12, if the cow suffering from mastitis meets “the sum of scores<1”, it is regarded as cured on Day 12. The cure rate on
  • Day 12 = number of cows cured on Day 12 number of cows in experimental group × 100 % .
  • Effective rate of treatment on Day 12 (total effective rate): On D12, if the cow suffering from mastitis meets “1≤the sum of the scores≤2”, the treatment is considered effective. The effective rate on
  • Day 12 = number of cows effectively treated on Day 12 number of cows in experimental group × 100 % .
  • With the cure rate as the main indicator, and the effectiveness, clinical symptom score, and somatic cell number as the secondary indicators, comprehensively evaluate the therapeutic effect of the test drug (Pulsatilla Saponin B4 injection) on clinical mastitis of naturally infected cows, and compare it with the therapeutic effect of the control drug (SHUANGDING Injection) to determine the clinical recommended dosage of the tested drug.
    • 4. Test Results
  • 4.1 Results of Treatment of Cows with Clinical Mastitis in Each Group
  • It can be seen from Table 7 that when using Pulsatilla Saponin B4 injection to treat clinical mastitis in dairy cows, regardless of the low-, medium- and high-dose, the cure rate in 7 days and the total cure rate are higher than that of the control group using SHUANGDING Injection, and the average cure time is shorter than the control group, indicating that Pulsatilla Saponin B4 injection is superior to SHUANGDING Injection in the treatment of clinical mastitis. The total cure rate of the high-dose group is higher than those of the medium- and low-dose groups. The total cure rate of the medium-dose group is the same as that of the low-dose group, but there is no recurrence, and the average cure time is shorter than that of the low-dose group, showing a certain dose-effect relationship.
  • TABLE 7
    Results of therapeutic effects of
    cows with clinical mastitis in each group
    Cure Total Total
    rate in Recurrence cure effective Average
    Group 7 days rate rate rate cure time
    Low-dose 83.33% 8.33% 75.00% 100% 6.33 days
    group
    Medium-dose 66.67% 0 75.00% 100% 6.11 days
    group
    High-dose 75.00% 0 91.67% 100% 6.91 days
    group
    Control group 41.67% 0 58.33%    66.67% 7.00 days

    4.2 Clinical Symptom Examination Score of Dairy Cows with Mastitis in Each Group
  • It can be seen from Table 8 that the clinical symptom examination score of dairy cows with mastitis in low-dose group was not significantly different between D0-D4 and between D5-D12 (p>0.05), but was significantly different between D5-D12 and D0-D2, between D7-D12 and D0-D4 (p<0.05), indicating that in low-dose group, cows with mastitis improved significantly at D5, and cured significantly at D7. The clinical symptom examination score of dairy cows with mastitis in medium-dose group was not significantly different between D0-D1, between D2-D5, and between D4-D12 (p>0.05), but was significantly different between D3-D12 and D0-D2, between D6-D12 and D0-D3 (p<0.05), indicating that in medium-dose group, cows improved significantly at D3, and cured significantly at D6. The clinical symptom examination score of dairy cows with mastitis in high-dose group was not significantly different between D0-D3, between D1-D5, between D3-D6, and between D7-D12 (p>0.05), but was significantly different between D4-D12 and D0, between D6-D12 and D0-D2, and between D7-D12 and D0-D6 (p<0.05), indicating that in high-dose group, cows with mastitis generally started to improve at D4, the number of cured cows has increased significantly at D6, and some cows cured at D7. The clinical symptom examination score of dairy cows with mastitis in control group was not significantly different between D0-D4, between D2-D6, and between D3-D12 (p>0.05), but was significantly different between D5-D12 and D0-D4, and between D7-D12 and D0-D6 (p<0.05), indicating that in control group, cows improved at D5, and a certain number of cows cured at D7.
  • The clinical symptom examination score of medium-dose group at D0 was significantly higher than those of the low-dose group and high-dose group (p<0.05), indicating that the disease of cows in the medium-dose group was more serious; the clinical symptom examination score of medium-dose group at D1 was significantly higher than the other 3 groups (p<0.05), the clinical symptom examination score of medium-dose group at D2 was significantly higher than those of the low-dose group and high-dose group (p<0.05), indicating that in the early stage of treatment, the medium-dose group has an obvious effect on improving the clinical symptoms of cows with mastitis; the differences in the clinical symptom examination score of cows between the four groups at D3-D5 and D7 were not significant (p>0.05); the clinical symptom examination score of the cows in the control group at D12 was significantly higher than that of the high-dose group (p<0.05), indicating that the therapeutic effect of the control group is inferior to that of the Pulsatilla treatment group.
  • TABLE 8
    Clinical symptom examination score of dairy cows in each group
    G N D0 D1 D2 D3 D4 D5 D6 D7 D12
    L 1 1.58 ± 0.67 1.42 ± 0.51 1.17 ± 0.58 1.08 ± 0.29 1.08 ± 0.29 0.83 ± 0.58 0.83 ± 0.83 0.33 ± 0.89 0.50 ± 1.00
    2 AB AB ABB ABA ABA BCA BCAB CA CAB
    M 1 2.92 ± 2.11 2.67 ± 1.61 2.17 ± 1.11 1.42 ± 0.90 1.08 ± 0.67 1.00 ± 0.74 0.50 ± 0.52 0.33 ± 0.49 0.25 ± 0.45
    2 AA AA ABA BA BCA BCA CB CA CAB
    H 1 1.50 ± 0.67 1.33 ± 0.65 1.42 ± 0.67 1.17 ± 0.58 1.00 ± 0.43 1.00 ± 0.60 0.83 ± 0.58 0.33 ± 0.65 0.08 ± 0.29
    2 AB ABB ABB ABCA BCA BCA CAB DA DB
    C 1 2.08 ± 0.67 1.83 ± 0.72 1.75 ± 0.75 1.50 ± 0.67 1.42 ± 0.90 1.33 ± 0.78 1.17 ± 0.83 0.92 ± 1.00 0.92 ± 1.24
    2 AAB ABB ABAB ABCA ABCA BCA BCA CA CA
  • Note: “G” means “Group”, “N” means “Number of cattle”, “L” means “Low-dose group”, “M” means “Medium-dose group”, “H” means “High-dose group”; “C” means “Control group”; and
  • In the same line, superscripts with different capital letters indicate significant differences (p<0.05), and superscripts with the same capital letters indicate no significant differences (p>0.05); in the same column, subscripts with different capital letters indicate significant differences (p<0.05), and subscripts with the same capital letters indicate no significant differences (p>0.05). The same applies to the table below.
    • 4.3 Somatic Cell Detection Results of Cow Milk in Each Group
  • TABLE 9
    Somatic cell detection results of milk from
    cured cows in each group (104/mL)
    Number
    of
    Group cattle D0 D7 D12
    Low-dose 9 255.8 ± 38.9A A   90.5 ± 55.8B AB 47.5 ± 35.6B AB
    group
    Medium- 9 244.6 ± 42.0A A  65.8 ± 51.5B B 38.1 ± 23.0B B 
    dose group
    High-dose 11  310.6 ± 132.4A A 182.3 ± 151.7B A 48.8 ± 58.9C AB
    group
    Control 7 267.9 ± 123.7A A 180.7 ± 119.2A A 88.8 ± 67.4B A 
    group
  • It can be seen from Table 9 that the somatic cells in the milk of cows in each group showed a downward trend at D0-D7. The difference between D7 and D12 in the low-dose group, medium-dose group and control group was not significant, but D7 was significantly different from D0, indicating that with the treatment of the drug, milk somatic cell improved significantly at D7 and did not relapse afterwards. In the high-dose group, D0, D7, and D12 were all significantly different, which on the one hand showed a significant improvement in milk somatic cells, and on the other hand was also related to the longer average cure time of the cows in this group. The difference in milk somatic cells of the four groups of cows at D0 was not significant, indicating that from the perspective of milk somatic cells, the cows in each group had similar disease status at the time of onset. At D7, the milk somatic cells of the medium-dose group cows were significantly lower than those of the high-dose group and the control group, which was related to the shorter average cure time of the medium-dose group. At D12, the milk somatic cells of the cows in the control group were significantly higher than that of the medium-dose group, indicating that the therapeutic effect of Pulsatilla Saponin B4 injection on dairy cow mastitis is better than SHUANGDING Injection.
  • From the therapeutic effect of Pulsatilla Saponin B4 injection on clinical mastitis of dairy cows, the number of milk somatic cells, clinical cure rate and cure test observations, it can be seen that all Pulsatilla Saponin B4 injections with different concentrations have obvious therapeutic effect on dairy cow clinical mastitis, and the effect is better than the positive control SHUANGDING Injection. In addition, Pulsatilla Saponin B4 injection is non-toxic and non-drug-resistant, and there is no need to discard the milk during the treatment and at the end of the treatment, which not only reduces the economic losses for farmers, but also reduces the risk of drug resistance.
  • FIGS. 2 and 3 show the comparison of milk of cows with clinical mastitis before and after treatment with Pulsatilla Saponin B4 injection. As can be seen from FIG. 2 and FIG. 3, on the first day of treatment, the cows with clinical mastitis had more flocs in the milk. As the treatment time increases, the flocs gradually decreased, and the milk gradually returned to normal. After the sixth day of treatment, the milk returned to normal. It showed that Pulsatilla Saponin B4 injection has a significant effect in treating clinical mastitis and improving milk quality.
    • Test Example 3. Study of Pulsatilla Saponin B4 of the Present Invention in the Treatment of Persistent Clinical Mastitis and Latent Mastitis 1. Test Drugs
  • Pulsatilla Saponin B4 injection prepared by the preparation method of Example 3 at a concentration of 50 mg/mL;
    • 2. Test Cows
  • The test selected 8 existing cows suffering from clinical mastitis in the dairy farm of Shijiazhuang Tianquan Dairy Cows Co., Ltd. These 8 cows have been treated for about a month but have not been cured (2 of them were close to dry, i.e., almost no milk was produced). These 8 cows have been treated by farm veterinarians, the treatment drugs and methods include udder infusing Cefquinome Sulfate Intramammary Infusion, intravenous injecting cephalosporins injection, and gavage with Gongying San (
    Figure US20210038622A1-20210211-P00003
    ), etc.
  • The test randomly selected 6 cows with latent mastitis in Tianquan dairy farm, all of which had at least one udder area of “++” or above in the last LMT test by the veterinarian.
    • 3. Test Contents
  • To study the effect of Pulsatilla Saponin B4 injection on persistent clinical mastitis and the effect of Pulsatilla Saponin B4 injection on latent mastitis.
    • 4. Test Drugs, Dosage and Mode of Administration
  • In the test, the Pulsatilla Saponin B4 injection prepared by the preparation method of Example 3 was used to treat 6 cows with persistent clinical mastitis and 2 cows with persistent clinical mastitis and close to dry. No matter how many udder areas were inflamed, intramuscular injection (60 mL) was taken once a day.
  • For 6 randomly selected cows with latent mastitis, no matter how many udder areas were inflamed, intramuscular injection (30 mL) was taken once a day.
  • TABLE 10
    Test drugs, dosage and mode of administration
    Number Injection Mode of
    Test cow of cattle volume administration
    Persistent 6 60 mL Intramuscular injection,
    clinical mastitis once a day
    Close to dry 2 60 mL Intramuscular injection,
    once a day
    Latent mastitis 6 30 mL Intramuscular injection,
    once a day
    Total 15  // Intramuscular injection,
    once a day
    • 5. Test Results
  • 5.1 Treatment Result of Cows with Persistent Clinical Mastitis
  • In the test, 8 cows with clinical mastitis and have not been cured for a long time were selected and treated. After 3 administrations, four cows were cured, one cow improved significantly, and one cow showed no significant effect; it was not effective for two cows close to dry. The results of the study showed that Pulsatilla Saponin B4 has good effects on dairy cow mastitis for which treatment with antibiotics or other means are ineffective.
  • Treatment results for some cows that have not been cured for a long time: For the cow with an ear-tag numbered 8558, the milk of the cow before treatment was thin and contained a small amount of flocs, and the LMT test result was “+++”; after intramuscular injection of 60 mL Pulsatilla Saponin B4 injection once, there was no visible flocs in the milk, and the color of the milk was slightly yellow. After the second administration, milk returned to normal, and the result of LMT test by the veterinarian was “++”. Then the cow was transferred to the farm housing by the veterinarian.
  • FIG. 4 shows the treatment of the cow numbered 8558, which has not been cured for a long time. It can be seen from FIG. 4 that as the treatment time increases, the milk secretion of the cow numbered 8558 gradually became normal. After 2 times of administration, the milk returned to normal, the cow was clinically cured.
  • 5.2 Treatment of Cows with Latent Mastitis
  • According to the LMT test results of farm veterinarian, 6 cows with latent mastitis were randomly selected, all of which had at least one udder area of “++” or above. Pulsatilla Saponin B4 injection 30 mL was administrated via Intramuscular injection. Three days later, the LMT test results of 5 cows improved significantly. The improvement of the other cow (No. 532006) was not significant, but no aggravation occurred.
  • TABLE 11
    Test results of latent mastitis
    Somatic
    cells LMT results
    Ear-tag before three days after
    number Last LMT result the test administration
    131213 Both front right and 1323 Front right−,
    rear right +++ rear right++
    0909041 Rear left++, 1294 Rear left+,
    front right+++ front right−
    131208 Front right+++, 847 Front right−,
    rear right++ rear right+
    160128 Four udder areas +++ 5450 Four udder areas ++
    532006 Four udder areas +++ 2041 Four udder areas +++
    1106021 Front left++, rear left+++ — Front left−, rear left++
    Note:
    Since there is no somatic cell detector in the farm, the test needs to be performed in other farms. The veterinarian of the dairy farm has not completed the somatic cell testing, but the LMT test results after three days of administration showed significant improvement in 5 cows with latent mastitis.
  • Remarks on special cows: For cow No. 1106021, before administration, two udder areas on the left suffered from latent mastitis, the LMT test results of front left and rear left were “++” and “+++” respectively; rear right was completely dry and no milk can be squeezed out; the milk of the first three squeezing of front right was thick and yellow in color, and after squeezing out a few more, bloody mucus-like fluid without milk characteristics appeared. Intramuscular injecting Pulsatilla Saponin B4 injection 30 mL once a day, and after 3 days of administration, there was no improvement in the front right, the LMT test results of front left and rear left were “−” and “++” respectively, somatic cells were significantly reduced, and the effect was significant.
  • The other 5 cows suffering from latent mastitis were injected intramuscularly once a day with Pulsatilla Saponin B4 injection 30 mL. After three days of treatment, 4 cows improved and the results of LMT showed that the somatic cells were reduced; the improvement of the other cow (No. 532006) was not significant. FIG. 5 shows the treatment results of some cows suffering from latent mastitis after three days of treatment with Pulsatilla Saponin B4 injection. It can be seen from FIG. 5 that the condition of cows suffering from latent mastitis improved after administration of medication.
  • The results of the study showed that Pulsatilla Saponin B4 has a good effect on latent mastitis.
  • The diseased cows have been treated by farm veterinarians via udder infusing Cefquinome Sulfate Intramammary Infusion, intravenous injecting cephalosporins injection, and gavage with Gongying San (
    Figure US20210038622A1-20210211-P00004
    ) for about a month, but the treatment was ineffective, and the disease was then turned into chronic mastitis, which was manifested by thin milk and continuous floc in the milk. The reason for the above situation may be: first, the variety of drug used in the farm for the treatment of mastitis was simplex, only antibacterial drug was used in the treatment process without paying attention to anti-inflammatory; second, the variety of antibiotics used was simplex, and the pathogenic bacteria were not isolated and identified, resulting in bacterial resistance and insensitivity to drugs; third, long-term treatment leads to hyperplasia of mammary tissue, causing chronic inflammation, which in turn makes it more difficult for the drug to reach the effective site, making the condition stubborn. When Pulsatilla Saponin B4 injection was used to treat 8 cows recruited in the test, after 3 administrations, four cows were cured, one cow improved significantly, and one cow showed no significant effect; it was not effective for two cows close to dry. The results of the study showed that Pulsatilla Saponin B4 has a good effect on dairy cow mastitis for which treatment with antibiotics or other means are ineffective.
  • Latent mastitis is one of the most common types of mastitis in dairy cows. This type of mastitis generally has no clinical symptom, the difference between its milk and normal milk cannot be distinguished by the naked eye, and it needs laboratory reagents to diagnose. If this type of mastitis does not reach a certain proportion in the herd, it is generally not treated. Because of its concealed incidence, the economic loss caused by latent mastitis to dairy cows is very serious. When Pulsatilla Saponin B4 injection was used to treat 6 cows suffering from latent mastitis, four cows improved; one cow showed significant effect and reduced somatic cells in the LMT test; one cow had no significant improvement. The results of the study showed that Pulsatilla Saponin B4 has a good effect on latent mastitis.
  • In addition, during the treatment of dairy cow mastitis, randomly selected the tested Pulsatilla Saponin B4 injection and entrusted the Sichuan Provincial Veterinary Drug Inspection Institute to conduct more than 200 antibiotic tests, and no antibiotic component was detected. On the second day after the administration to dairy cows, all milk can pass the antibiotic residue test conducted on the farm. Pulsatilla Saponin B4 has little effect on the immunoglobulin and inflammatory factors in the cow milk, thus can ensure the stability of the milk composition. In addition, since there is no residue, it will not affect the quality of fresh milk in dairy farms.
  • At present, antibiotics are mostly used for the treatment of mastitis. Among them, broad-spectrum sterilization and cell-damaging nucleic acid antibiotics are more commonly used. During the treatment and 4 to 5 days after the treatment, milk needs to be discarded, causing a large economic loss to the farmers and the risk of drug resistance. Pulsatilla Saponin B4 is a natural active ingredient extracted from Chinese herbal medicine Pulsatilla, is non-toxic and non-drug-resistant. The compound Pulsatilla Saponin B4 of the present invention has strong biological activity and has excellent therapeutic effect on dairy cow mastitis. There is no need to discard the milk during the treatment and at the end of the treatment, which not only reduces the economic losses for farmers, but also reduces the risk of drug resistance. In addition, Pulsatilla Saponin B4 not only has an excellent therapeutic effect on clinical mastitis, but also has an excellent therapeutic effect on persistent clinical mastitis and latent mastitis. At the same time, Pulsatilla saponin injection has the advantages of safety, high efficiency, no residue, no drug resistance, and no toxic and side effects when used in the treatment of dairy cow mastitis.

Claims (10)

1. Use of the compound Pulsatilla Saponin B4 represented by formula I, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral and/or bacterial diseases:
Figure US20210038622A1-20210211-C00003
2. The use according to claim 1, characterized in that the medicament is a preparation prepared from the compound Pulsatilla Saponin B4 of claim 1, or a pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable auxiliary materials.
3. The use according to claim 2, characterized in that the preparation is an injection, an intramammary infusion, powder, ointment, lotion; preferably, the preparation is an injection, an intramammary infusion; more preferably, the preparation is an injection.
4. The use according to claim 1, characterized in that the disease is dairy cow mastitis.
5. The use according to claim 4, characterized in that the dairy cow mastitis is clinical mastitis, latent mastitis.
6. The use according to claim 5, characterized in that the clinical mastitis is clinical mastitis treated for the first time, persistent clinical mastitis.
7. A medicament for treating viral and/or bacterial diseases, characterized in that it is a preparation prepared from the compound Pulsatilla Saponin B4 of claim 1, or a pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable auxiliary materials.
8. The medicament according to claim 7, characterized in that the preparation is an injection, an intramammary infusion, powder, ointment, lotion; preferably, the preparation is an injection, an intramammary infusion; more preferably, the preparation is an injection.
9. The medicament according to claim 7, characterized in that the disease is dairy cow mastitis.
10. The medicament according to claim 9, characterized in that the dairy cow mastitis is clinical mastitis, latent mastitis; preferably, the clinical mastitis is clinical mastitis treated for the first time, persistent clinical mastitis.
US16/966,855 2018-01-31 2019-01-25 Uses of pulsatilla chinensis extract in preparing drug for treating viral and/or bacterial diseases Abandoned US20210038622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810097221 2018-01-31
CN201810097221.3 2018-01-31
PCT/CN2019/073239 WO2019149156A1 (en) 2018-01-31 2019-01-25 Uses of pulsatilla chinensis extract in preparing drug for treating viral and/or bacterial diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/073239 A-371-Of-International WO2019149156A1 (en) 2018-01-31 2019-01-25 Uses of pulsatilla chinensis extract in preparing drug for treating viral and/or bacterial diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/662,725 Division US11793822B2 (en) 2018-01-31 2022-05-10 Uses of Pulsatilla Chinensis extract in preparing drug for treating viral and/or bacterial diseases

Publications (1)

Publication Number Publication Date
US20210038622A1 true US20210038622A1 (en) 2021-02-11

Family

ID=67443779

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/966,857 Active 2039-03-24 US11510933B2 (en) 2018-01-31 2019-01-25 Use of Pulsatilla chinensis extract in the preparation of drugs for treatment of viral and/or bacterial diseases
US16/966,855 Abandoned US20210038622A1 (en) 2018-01-31 2019-01-25 Uses of pulsatilla chinensis extract in preparing drug for treating viral and/or bacterial diseases
US17/662,725 Active US11793822B2 (en) 2018-01-31 2022-05-10 Uses of Pulsatilla Chinensis extract in preparing drug for treating viral and/or bacterial diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/966,857 Active 2039-03-24 US11510933B2 (en) 2018-01-31 2019-01-25 Use of Pulsatilla chinensis extract in the preparation of drugs for treatment of viral and/or bacterial diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/662,725 Active US11793822B2 (en) 2018-01-31 2022-05-10 Uses of Pulsatilla Chinensis extract in preparing drug for treating viral and/or bacterial diseases

Country Status (12)

Country Link
US (3) US11510933B2 (en)
EP (2) EP3747445B1 (en)
JP (1) JP7021360B2 (en)
CN (2) CN110090222B (en)
AU (2) AU2019214081B2 (en)
BR (2) BR112020015536A2 (en)
CA (2) CA3089522C (en)
ES (1) ES2964618T3 (en)
MX (1) MX2020008047A (en)
PL (1) PL3747445T3 (en)
UA (1) UA127576C2 (en)
WO (2) WO2019149156A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510933B2 (en) * 2018-01-31 2022-11-29 Sichuan Inlu Weite Pharmaceutical Technology Co., Ltd. Use of Pulsatilla chinensis extract in the preparation of drugs for treatment of viral and/or bacterial diseases

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111228280B (en) * 2020-01-17 2021-08-13 陕西科技大学 Application of pulsatilla saponin A3 in inhibition of growth of multidrug-resistant providencia rettgeri
CN111249289A (en) * 2020-02-14 2020-06-09 广西英路维特药物有限公司 Oral care product or medicament for anti-inflammation and/or anti-allergy
CN111249291B (en) * 2020-03-19 2023-07-18 广西馨海药业科技有限公司 Application of pulsatilla chinensis saponin B4 in preparation of medicines for treating/preventing bacterial pneumonia
CN113633682B (en) * 2021-07-22 2022-08-26 广西馨海药业科技有限公司 Cream for treating herpes zoster and preparation method thereof
CN114159453A (en) * 2021-12-24 2022-03-11 广西馨海药业科技有限公司 Application of pulsatilla chinensis saponin B4 in preparation of medicine for treating or preventing psoriasis
CN114533748B (en) * 2022-02-15 2023-11-28 广西馨海药业科技有限公司 Application of pulsatilla chinensis saponin B4 in preparation of medicines for treating or preventing hysteromyoma

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083050A1 (en) * 2005-02-03 2006-08-10 Sk Chemicals, Co., Ltd. Pulsatilla spp. extracts effective in brain function
CN101337033A (en) 2007-07-08 2009-01-07 宫兆荣 Canine parvovirus resisting preparation
CN101411762A (en) * 2007-10-19 2009-04-22 天津生机集团有限公司 Chinese medicinal composition for treating Canine parvovirus disease and preparation thereof
AU2014227506B2 (en) * 2008-12-04 2015-05-07 Boehringer Ingelheim Animal Health USA Inc. Intramammary teat sealant
CN101537059B (en) * 2009-04-20 2011-05-25 西南大学 Anti-enteritis canine parvovirus Chinese medicinal composition and preparation method and applications thereof
CN101564524B (en) * 2009-06-05 2011-03-16 中国人民解放军军事医学科学院军事兽医研究所 Traditional Chinese medicine injection for treating canine parvovirus disease and preparation method thereof
CN101670026A (en) * 2009-08-28 2010-03-17 天津生机集团股份有限公司 Chinese and western medicine composition for treating canine parvovirus infection and preparation method thereof
CN101695550A (en) * 2009-10-29 2010-04-21 扬中牧乐药业有限公司 Pure Chinese medicinal preparation for adjuvant therapy of enteritis type canine parvovirus disease and preparation method thereof
CN102100826A (en) * 2009-12-16 2011-06-22 青岛康地恩药业有限公司 Chinese medicinal compound preparation for treating canine parvovirus enteritis and preparation method thereof
CN101732517B (en) 2009-12-30 2012-03-28 东北农业大学 Chinese medicinal composition for treating canine distemper and preparation method thereof
CN101926861A (en) * 2010-08-31 2010-12-29 四川华神农大动物保健药品有限公司 Method for preparing Chinese medicinal veterinary medicament for enhancing non-specific immune function
CN102077915A (en) * 2010-09-19 2011-06-01 周剑峰 Feed additive for preventing porcine parvovirus infection
CN102100753B (en) 2011-03-05 2012-07-04 中国农业科学院兰州畜牧与兽药研究所 Medicine for treating endometritis of milk cow
CN102234305A (en) * 2011-05-06 2011-11-09 南京泽朗医药科技有限公司 Method for preparing high-purity anemoside B4
CN102397532B (en) * 2011-11-16 2013-05-22 青岛绿曼生物工程有限公司 Compound propolis composition for treating muscovy duck parvovirus disease and preparation method thereof
CN102512547B (en) * 2011-12-14 2013-06-26 北安市飞龙动物药厂 Traditional Chinese medicine composition for treating canine distemper virus and preparation method thereof
CN103656116A (en) * 2012-09-20 2014-03-26 张波 Preparation method of traditional Chinese medicine prescription for treating canine distemper
CN102898496A (en) * 2012-10-12 2013-01-30 苏州世林医药技术发展有限公司 Preparation method for oleanolic acid type saponin
CN103405666B (en) * 2013-07-25 2015-04-15 天津集合科技有限公司 Traditional Chinese medicine composition for treating canine distemper and preparation method thereof
CN103948876B (en) * 2014-05-14 2015-04-15 深圳市红瑞生物科技有限公司 Medicine for treating parvovirus and preparation method thereof
CN104083564A (en) 2014-06-20 2014-10-08 钟云仙 Traditional Chinese medicine for treating animal foot rot by using polypodium pseudoamoenum ching
CN104161871B (en) * 2014-08-06 2016-04-27 新乡医学院 Tinea capitis (tinea alba) external is rubbed with the hands and is coated with medicated wine and preparation method thereof
KR102213617B1 (en) * 2014-08-12 2021-02-05 주식회사 엘지생활건강 Cosmetic or pharmaceutical composition for skin whitening or anti-inflammation comprising pulchinenoside B4
CN105213410B (en) * 2015-10-20 2018-12-18 刘琦 Application of the anemoside B4 as immunomodulator in treatment acute inflammation drug
CN106860844A (en) * 2015-12-10 2017-06-20 重庆英华农业开发有限公司 For the pure Chinese medicine formula of canine parvovirus infections disease
CN105535004B (en) * 2016-02-02 2018-06-26 刘琦 Application of the anemoside B4 as EV71 viral inhibitors in anti-hand-foot-and-mouth-disease drug is prepared
CN106039074A (en) * 2016-07-12 2016-10-26 张绪伟 Tablets for treating canine parvovirus
CN107029040B (en) * 2017-05-02 2020-06-16 湖南农业大学 Compound traditional Chinese medicine powder for treating cow subclinical mastitis
CN107137413B (en) 2017-06-21 2020-07-14 苏州大学 Anemonin B4Application in preparing medicine for treating pain
WO2019006741A1 (en) * 2017-07-07 2019-01-10 刘琦 Preparation of pulsatilla saponin b4 for injection
CN108938654B (en) 2017-07-07 2021-06-08 刘琦 Pulsatillae saponin B4 injection preparation
CN107441086A (en) * 2017-07-27 2017-12-08 哈尔滨珍宝制药有限公司 A kind of pharmaceutical composition and its production and use
ES2964618T3 (en) * 2018-01-31 2024-04-08 Sichuan Inlu Weite Pharmaceutical Tech Co Ltd Saponin B4 from pulsatilla for the treatment of mastitis in dairy cows

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510933B2 (en) * 2018-01-31 2022-11-29 Sichuan Inlu Weite Pharmaceutical Technology Co., Ltd. Use of Pulsatilla chinensis extract in the preparation of drugs for treatment of viral and/or bacterial diseases

Also Published As

Publication number Publication date
MX2020008047A (en) 2020-12-07
EP3747446A1 (en) 2020-12-09
JP7021360B2 (en) 2022-02-16
US11510933B2 (en) 2022-11-29
CA3090025C (en) 2023-09-19
CA3089522C (en) 2023-03-14
EP3747445A4 (en) 2021-10-06
US20210038623A1 (en) 2021-02-11
EP3747446B1 (en) 2023-08-23
RU2020126266A (en) 2022-02-28
CN110090221A (en) 2019-08-06
AU2019214082B2 (en) 2023-11-30
US20220273685A1 (en) 2022-09-01
CN110090222A (en) 2019-08-06
UA127576C2 (en) 2023-10-18
AU2019214081A1 (en) 2020-08-20
BR112020015519A2 (en) 2021-01-26
CA3089522A1 (en) 2019-08-08
CA3090025A1 (en) 2019-08-08
WO2019149155A1 (en) 2019-08-08
AU2019214081B2 (en) 2023-11-23
EP3747445B1 (en) 2023-08-23
PL3747445T3 (en) 2024-04-08
BR112020015536A2 (en) 2021-02-02
US11793822B2 (en) 2023-10-24
EP3747445A1 (en) 2020-12-09
EP3747446A4 (en) 2021-10-06
JP2021512880A (en) 2021-05-20
ES2964618T3 (en) 2024-04-08
CN110090222B (en) 2022-04-05
AU2019214082A1 (en) 2020-09-03
WO2019149156A1 (en) 2019-08-08
CN110090221B (en) 2022-04-05

Similar Documents

Publication Publication Date Title
US11793822B2 (en) Uses of Pulsatilla Chinensis extract in preparing drug for treating viral and/or bacterial diseases
CN103142683B (en) Be used for the treatment of Chinese medicinal perfusion liquid containing Herba Sophorae alopecuroidis total alkali of bovine mastitis and endometritis and preparation method thereof
CN105726631A (en) Application of officinal magnolia bark extract to prepare medicine for treating cow mastitis
CN102274264B (en) Application of platycodon root total saponin in medicaments for treating and preventing mycoplasma pneumoniae infectious diseases
RU2799050C2 (en) Application of pulsatilla chinensis extract for obtaining a drug for the treatment of viral and/or bacterial diseases
CN116763777A (en) Application of 17-hydro-9-dehydroandrographolide-19-sodium sulfate in preparing medicament for treating cow mastitis
CN109470788A (en) A kind of method of quality control of FUKE QIANJIN PIAN
CN105381301A (en) Method for preparing traditional Chinese medicinal preparation for treating chronic glomerulonephritis
CN103271983A (en) Perfusate for treating endometritis and kysthitis of pig as well as preparation method and application thereof
CN109125427B (en) Penyanjing suppository and preparation method thereof
CN107802632B (en) Traditional Chinese medicine effective component composition for treating rheumatic arthritis and rheumatoid arthritis and application thereof
CN109254098A (en) A kind of method of quality control of &#39; Qianjin &#39; capsule to treat ganopathy
Jeong et al. Gallic acid inhibits STAT3 phosphorylation and alleviates DDS-induced colitis via regulating cytokine production
CN111202789A (en) New application of bowel relaxing formula with five fruits and vegetables as raw materials for increasing intestinal moisture and lubricating intestinal tract
CN118178437A (en) Application of ginsenoside Rk1 in preparation of medicines for treating ulcerative colitis
CN109364147A (en) A kind of &#39; Qianjin &#39; capsule to treat ganopathy and preparation method thereof
CN118416050A (en) Pharmaceutical composition, pharmaceutical preparation and application thereof in preparation of antitumor drugs
CN117137965A (en) Application of rhizoma corydalis extract in preparation of medicine for treating atopic dermatitis
US20220323525A1 (en) Fuke qianjin tablet and quality control method therefor
CN110833570A (en) Preparation method of three-flower Chinese angelica perfusate
WO2020098831A1 (en) Gynecological qianjin capsule and quality control method therefor
CN109172677A (en) &#39; Qianjin &#39; capsule to treat ganopathy and preparation method thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: SICHUAN INLU WEITE PHARMACEUTICAL TECHNOLOGY CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YANG, SHILIN;SU, ZHETONG;REEL/FRAME:054961/0132

Effective date: 20201221

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION